Detailed Notes on Retene
Contraindicated (one)bortezomib will improve the stage or effect of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Robust or moderate CYP2C19 inhibitors might enhance mavacamten systemic exposure, causing coronary heart failure resulting from systolic dysfunction.To lower the potential risk of dizziness and lightheade